The use of platelet-rich fibrin in the surgical treatment of
medication-related osteonecrosis of the jaw: 40 patients
prospective study

J 2021

The use of platelet-rich fibrin in the surgical treatment of medication-related osteonecrosis of the jaw: 40 patients prospective study

ZELINKA, Jiří, Jiří BLAHÁK, Vojtěch PEŘINA, Rita PACASOVÁ, Jana TREGLEROVÁ et. al.

Základní údaje

Originální název

The use of platelet-rich fibrin in the surgical treatment of medication-related osteonecrosis of the jaw: 40 patients prospective study

Autoři

ZELINKA, Jiří, Jiří BLAHÁK, Vojtěch PEŘINA, Rita PACASOVÁ, Jana TREGLEROVÁ a Oliver BULIK

Vydání

Biomedical Papers, Univerzita Palackého v Olomouci, 2021, 1213-8118

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 1.648

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.5507/bp.2020.023

UT WoS

000715922000013

Klíčová slova anglicky

medication related osteonecrosis of the jawplatelet rich fibrinsurgical treatment

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 3. 4. 2023 08:37, Mgr. Tereza Miškechová

Anotace

V originále

Medication-related osteonecrosis of the jaw (MRONJ) is defined as exposed bone in the maxillofacial region persisting for more than eight weeks in patients who are or were treated with antiresorptive or antiangiogenic agents and had no radiation therapy to the craniofacial region or obvious metastatic disease of the jaws. It is a recognised side effect of antiresorptive or antiangiogenic medication. To date, there is no specific gold standard treatment for MRONJ cases. The aim of this study was to evaluate the successful rate of surgical treatment with adjuvant local application of platelet rich fibrin.

Citovat

ZELINKA, Jiří, Jiří BLAHÁK, Vojtěch PEŘINA, Rita PACASOVÁ, Jana TREGLEROVÁ a Oliver BULIK. The use of platelet-rich fibrin in the surgical treatment of medication-related osteonecrosis of the jaw: 40 patients prospective study. Biomedical Papers. Univerzita Palackého v Olomouci, 2021, roč. 165, č. 3, s. 322-327. ISSN 1213-8118. Dostupné z: https://dx.doi.org/10.5507/bp.2020.023.

@article{1771658,
   author = {Zelinka, Jiří and Blahák, Jiří and Peřina, Vojtěch and Pacasová, Rita and Treglerová, Jana and Bulik, Oliver},
   article_number = {3},
   doi = {http://dx.doi.org/10.5507/bp.2020.023},
   keywords = {medication related osteonecrosis of the jawplatelet rich fibrinsurgical treatment},
   language = {eng},
   issn = {1213-8118},
   journal = {Biomedical Papers},
   note = {Bez afiliace k MU.},
   title = {The use of platelet-rich fibrin in the surgical treatment of medication-related osteonecrosis of the jaw: 40 patients prospective study},
   url = {https://biomed.papers.upol.cz/artkey/bio-202103-0013_the-use-of-platelet-rich-fibrin-in-the-surgical-treatment-of-medication-related-osteonecrosis-of-the-jaw-40-pa.php?back=%2Fsearch.php%3Fquery%3DZelinka%2Bin%253Aauth%2Bname%2Bkey%2Babstr%26sfrom%3D0%26},
   volume = {165},
   year = {2021}
}

TY  - JOUR
ID  - 1771658
AU  - Zelinka, Jiří - Blahák, Jiří - Peřina, Vojtěch - Pacasová, Rita - Treglerová, Jana - Bulik, Oliver
PY  - 2021
TI  - The use of platelet-rich fibrin in the surgical treatment of medication-related osteonecrosis of the jaw: 40 patients prospective study
JF  - Biomedical Papers
VL  - 165
IS  - 3
SP  - 322-327
EP  - 322-327
PB  - Univerzita Palackého v Olomouci
SN  - 12138118
N1  - Bez afiliace k MU.
KW  - medication related osteonecrosis of the jawplatelet rich fibrinsurgical treatment
UR  - https://biomed.papers.upol.cz/artkey/bio-202103-0013_the-use-of-platelet-rich-fibrin-in-the-surgical-treatment-of-medication-related-osteonecrosis-of-the-jaw-40-pa.php?back=%2Fsearch.php%3Fquery%3DZelinka%2Bin%253Aauth%2Bname%2Bkey%2Babstr%26sfrom%3D0%26
N2  - Medication-related osteonecrosis of the jaw (MRONJ) is defined as exposed bone in the maxillofacial region persisting for more than eight weeks in patients who are or were treated with antiresorptive or antiangiogenic agents and had no radiation therapy to the craniofacial region or obvious metastatic disease of the jaws. It is a recognised side effect of antiresorptive or antiangiogenic medication. To date, there is no specific gold standard treatment for MRONJ cases. The aim of this study was to evaluate the successful rate of surgical treatment with adjuvant local application of platelet rich fibrin.
ER  -

ZELINKA, Jiří, Jiří BLAHÁK, Vojtěch PEŘINA, Rita PACASOVÁ, Jana TREGLEROVÁ a Oliver BULIK. The use of platelet-rich fibrin in the surgical treatment of medication-related osteonecrosis of the jaw: 40 patients prospective study. \textit{Biomedical Papers}. Univerzita Palackého v Olomouci, 2021, roč.~165, č.~3, s.~322-327. ISSN~1213-8118. Dostupné z: https://dx.doi.org/10.5507/bp.2020.023.

Podrobný výpis o publikaci